WallStreetZenWallStreetZen

NASDAQ: APGE
Apogee Therapeutics Inc Stock

$21.30+0.62 (+3%)
Updated Sep 29, 2023
APGE Price
$21.30
Fair Value Price
N/A
Market Cap
$1.08B
52 Week Low
$18.99
52 Week High
$25.54
P/E
N/A
P/B
-16.76x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-0.27
Operating Cash Flow
N/A
Beta
-0.22
Next Earnings
Nov 29, 2023
Ex-Dividend
N/A
Next Dividend
N/A

APGE Overview

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.

Zen Score

Industry Average (25)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how APGE scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

APGE's short-term assets ($130.67M) exceed its short-term liabilities ($17.62M)
Short-term Liabilities Financials
APGE's short-term assets ($130.67M) exceed its long-term liabilities ($0.00)
Long-term Liabilities Financials
APGE's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
There are 30 more APGE due diligence checks available for Premium users.

Be the first to know about important APGE news, forecast changes, insider trades & much more!

APGE News

Valuation

APGE price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
-16.76x
Industry
5.09x

APGE's financial health

Profit margin

Revenue
$0.0
Net Income
-$18.9M
Profit Margin
0%

Assets to liabilities

Assets
$130.7M
Liabilities
$17.6M
Debt to equity
-0.27
APGE's short-term assets ($130.67M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
APGE's short-term assets ($130.67M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
APGE's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
APGE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$14.6M
Investing
$0.0
Financing
-$1.7M

APGE vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
APGE$1.08B+3.00%N/A-16.76x
PROK$1.08B-2.76%-8.64x-0.81x
EQRX$1.08B-0.89%-4.04x0.87x
IRON$1.07B+0.02%-1.12x2.90x
DAWN$1.07B-1.05%-5.36x2.50x

Apogee Therapeutics Stock FAQ

What is Apogee Therapeutics's quote symbol?

(NASDAQ: APGE) Apogee Therapeutics trades on the NASDAQ under the ticker symbol APGE. Apogee Therapeutics stock quotes can also be displayed as NASDAQ: APGE.

If you're new to stock investing, here's how to buy Apogee Therapeutics stock.

What is the 52 week high and low for Apogee Therapeutics (NASDAQ: APGE)?

(NASDAQ: APGE) Apogee Therapeutics's 52-week high was $25.54, and its 52-week low was $18.99. It is currently -16.6% from its 52-week high and 12.16% from its 52-week low.

How much is Apogee Therapeutics's stock price per share?

(NASDAQ: APGE) Apogee Therapeutics stock price per share is $21.30 today (as of Sep 29, 2023).

What is Apogee Therapeutics's Market Cap?

(NASDAQ: APGE) Apogee Therapeutics's market cap is $1.08B, as of Sep 30, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Apogee Therapeutics's market cap is calculated by multiplying APGE's current stock price of $21.30 by APGE's total outstanding shares of 50,674,296.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.